Traws Pharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.0M
- Price
- $0.52
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.99%
- Volume
- 74.9K
About
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Quick stats
Shares outstanding15.4M
Computed float10.1M
Float / shares65.8%
Cash runway (months)0
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001130598
Websitehttps://www.trawspharma.com
AI Summary
AI-generated1/9
standardmixedearnings
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Traws Pharma reported Q2 revenue of $0 compared to $2.7 million in the prior year, while net loss widened to $3.0 million or $0.16 per share due to higher G&A expenses.
Cash and cash equivalents increased to $5.0 million following an April private placement, providing a runway into Q1 2027 before additional financing may be required.
Shareholders approved Series B and C warrant tranches, granting the company access to up to $50 million in additional capital contingent on achieving clinical and regulatory milestones.
Management expects to resubmit a revised toxicology package to the MHRA by the end of Q3 2026 and is preparing a response to the FDA to resolve the clinical hold on its US IND by year-end.
Red flags
- Cash runway extends only into Q1 2027
- FDA clinical hold on tivoxavir marboxil remains unresolved
- Revenue dropped to $0 from $2.7M in the prior-year quarter